Earnings ·
Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $35.0 million, or $1.81 per share, for the…
CRBPCorbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $35.0 million, or $1.81 per share, for the fiscal quarter ended June 30, 2026, compared to a net loss of $17.7 million in the prior year period. Operating expenses increased by $17.0 million to $36.2 million, primarily driven by a $10.0 million development milestone payment for CRB-701 and higher clinical development costs. The company holds $117.9 million in cash, cash equivalents, and investments, which is expected to fund operations into 2028. Corbus obtained FDA clearance to proceed with the registrational TEMPO-1 study of CRB-701 in second-line oropharyngeal cancer, expecting enrollment to begin in September 2026. Additionally, the company concluded the last patient visit for the CANYON-1 Phase 1b study of its obesity drug candidate CRB-913 and anticipates reporting data in September 2026. The firm appointed Leonardo Viana Nicacio as Chief Medical Officer, Nishant Saxena as Chief Business Officer, and Brent Pfeiffenberger to the Board of Directors. Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity.